



SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.

(Incorporated in the Republic of Singapore on 24 November 2011)

(Company Registration Number: 201134046D)

USE OF PROCEEDS FROM RENOUNCEABLE NON-UNDERWRITTEN RIGHTS CUM WARRANTS ISSUE

Unless otherwise defined or the context otherwise requires, all capitalised terms used herein bear the same meanings as in the Announcements (as defined below) and the Offer Information Statement (as defined below).

The Board of Directors (the “**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”, together with its subsidiaries, collectively, the “**Group**”) refers to the Company’s announcements dated 30 October 2025, 13 February 2026, 22 April 2026, 12 May 2026, 20 May 2026, 2 June 2026, 4 June 2026, 23 June 2026 and 24 June 2026 (collectively, the “**Announcements**”), and the Offer Information Statement dated 2 June 2026 (“**Offer Information Statement**”) in relation to, *inter alia*, the renounceable non-underwritten Rights cum Warrants Issue undertaken by the Company.

The Board wishes to provide the following update on the use of Net Proceeds raised from the issue of Rights Shares pursuant to the Rights cum Warrants Issue of approximately S\$14.94 million (after deducting estimated costs and expenses of approximately S\$330,000 relating to the Rights cum Warrants Issue):

	Amount allocated as disclosed in the Offer Information Statement (S\$)	Amount of Net Proceeds utilised as at the date of this announcement (S\$)	Balance amount of Net Proceeds as at the date of this announcement (S\$)
Use of Net Proceeds			
General working capital ⁽¹⁾	9,440,534	4,331,555 ⁽²⁾	5,108,979
Repayment of loan from a Shareholder ⁽³⁾	1,200,000	1,200,000	-
System maintenance and software upgrades	3,800,000	-	3,800,000
System revamp and CAPEX	500,000	-	500,000
Total	14,940,534	5,531,555	9,408,979

Notes:

- (1) As set out in the Offer Information Statement, the Company had received Prepayments from certain Undertaking Shareholders amounting to an aggregate of S\$3.90 million, which had been fully applied towards the Company’s working capital requirements, comprising mainly payroll expenses and maintenance fees for medical equipment. Please refer to the Offer Information Statement and the Company’s announcements dated 13 February 2026 and 22 April 2026 for further information in relation to the Prepayments.
- (2) For payment of i) payroll expenses of the Group’s employees amounting to approximately S\$1.93 million, ii) rental and other related expenses of the Group amounting to approximately S\$0.87 million, iii) the Group’s utilities charges amounting to approximately S\$0.68 million, and iv) continuing listing expenses and professional fees of the Group amounting to approximately S\$0.23 million.
- (3) The loan was granted by one of the Company’s Shareholders to the Company to fund its working capital. Please refer to the Offer Information Statement for further details in relation to the Shareholder’s loan.

The above utilisation of approximately S\$5.53 million of the Net Proceeds is in line with the intended use of Net Proceeds as set out in the Offer Information Statement.

The Company will continue to make periodic announcements on the utilisation of the Net Proceeds as and when such proceeds are materially disbursed, and whether such use is in accordance with the stated use and in accordance with the percentage allocated. The Company will also provide a status report on the use of the Net Proceeds in the Company's interim and full year financial results announcement(s) and in the Company's annual report(s), until such time the Net Proceeds have been fully utilised. Where there is any material deviation from the stated use of Net Proceeds, the Company will announce the reasons for such deviation.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
16 July 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.